Leung I, Sallo FB, Bonelli R, Clemons TE, Pauleikhoff D, Chew EY, Bird AC, Peto T., MacTel Study Group. Retina. 23 January 2018. 38 Suppl 1:S43-S50. doi: 10.1097/IAE.0000000000001842.
Dibyendu Mukherjee; Eleonora M. Lad; Ryan R. Vann; Stephanie J. Jaffe; Traci E. Clemons; Martin Friedlander; Emily Y. Chew; Glenn J. Jaffe; Sina Farsiu; for the MacTel Study Group.... View Article
Okada M, Heeren TFC, Egan CA, Rocco V, Bonelli R, Fruttiger M. Retina. 2018 Jan;38 Suppl 1:S89-S96. doi: 10.1097/IAE.0000000000001754.
Okada M, Robson AG, Egan CA, Sallo FB, Esposti SD, Heeren TFC, Fruttiger M, Holder GE. Retina. 2018 Jan;38 Suppl 1:S33-S42. doi: 10.1097/IAE.0000000000001746.
The Lowy Medical Research Institute would like to announce the latest MacTel Project Newsletter, which contains important updates on the Natural History Observation and Registry (NHOR) Study, Clinical Trials, and MacTel Projects.
Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), today announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macular Telangiectasia type 2 (MacTel). The multicenter, randomized clinical trial demonstrated a statistically significant reduction in the progressive loss of photoreceptors in treated versus untreated eyes. NT-501 utilizes the Company’s proprietary Encapsulated Cell Therapy (ECT) platform that can be customized to deliver specific therapeutic molecules to the back of the eye for retinal disease.
Vujosevic S, Heeren TFC, Florea D, Leung I, Pauleikhoff D, Sallo F, Bird A, Peto T. Retina. 2018 Jan;38 Suppl 1:S14-S19.... View Article
Sallo FB, Leung I, Clemons TE, Peto T, Chew EY, Pauleikhoff D, Bird AC, MacTel CNTF Research Group. Retina. 2018 Jan;38... View Article
Heeren TFC, Kitka D, Florea D, Clemons TE, Chew EY, Bird AC, Pauleikhoff D, Issa PC, Holz FG, Peto T.... View Article
Peto T, Heeren TFC, Clemons TE, Sallo FB, Leung I, Chew EY, Bird AC. Retina. 2017 May 11.
